Compare KOP & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOP | BCYC |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 456.4M |
| IPO Year | 2006 | 2019 |
| Metric | KOP | BCYC |
|---|---|---|
| Price | $34.42 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $52.50 | $19.10 |
| AVG Volume (30 Days) | 130.9K | ★ 379.1K |
| Earning Date | 02-26-2026 | 02-20-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,923,600,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.94 | N/A |
| P/E Ratio | $43.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.99 | $5.27 |
| 52 Week High | $35.61 | $13.11 |
| Indicator | KOP | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 82.58 | 31.77 |
| Support Level | $28.99 | $5.27 |
| Resistance Level | $31.88 | $5.95 |
| Average True Range (ATR) | 0.90 | 0.37 |
| MACD | 0.46 | -0.10 |
| Stochastic Oscillator | 92.33 | 0.26 |
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.